Holen Sie sich die Stockscreener-App
2.97
1.66%
-0.05
Handel nachbörslich:
3.00
0.03
+1.01%
Schlusskurs vom Vortag:
$3.02
Offen:
$3.03
24-Stunden-Volumen:
540.07K
Relative Volume:
0.97
Marktkapitalisierung:
$145.79M
Einnahmen:
$226.63M
Nettoeinkommen (Verlust:
$15.38M
KGV:
9.2813
EPS:
0.32
Netto-Cashflow:
$35.61M
1W Leistung:
-10.27%
1M Leistung:
+1.71%
6M Leistung:
-18.63%
1J Leistung:
-40.36%
1-Tages-Spanne:
$2.94
$3.07
1-Wochen-Bereich:
$2.94
$3.235
52-Wochen-Spanne:
$2.225
$7.73
Puma Biotechnology Inc Stock (PBYI) Company Profile
Firmenname
Puma Biotechnology Inc
Sektor
Branche
Telefon
(424) 248-6500
Adresse
10880 WILSHIRE BLVD., LOS ANGELES, CA
Vergleichen Sie PBYI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
2.97 | 145.79M | 226.63M | 15.38M | 35.61M | 0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-10-08 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-10 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-01-17 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2019-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-11-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-11-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-17 | Eingeleitet | Goldman | Sell |
| 2018-05-11 | Bestätigt | Stifel | Buy |
| 2017-11-10 | Bestätigt | Citigroup | Buy |
| 2017-11-10 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | Bestätigt | Stifel | Buy |
| 2017-09-11 | Bestätigt | Credit Suisse | Outperform |
| 2017-07-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-06-06 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | Bestätigt | RBC Capital Mkts | Sector Perform |
Alle ansehen
Puma Biotechnology Inc Aktie (PBYI) Neueste Nachrichten
Is Now The Time To Put Puma Biotechnology (NASDAQ:PBYI) On Your Watchlist? - Yahoo Finance
Jane Street Group LLC Buys 16,374 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Insufficient Growth At Puma Biotechnology, Inc. (NASDAQ:PBYI) Hampers Share Price - Simply Wall St
Zacks Research Has Negative Outlook of PBYI FY2024 Earnings - MarketBeat
Zacks Research Issues Pessimistic Estimate for PBYI Earnings - Defense World
FY2025 EPS Forecast for Puma Biotechnology Raised by Analyst - Defense World
FY2025 EPS Estimate for Puma Biotechnology Lifted by Analyst - MarketBeat
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer - MSN
Geode Capital Management LLC Has $2.34 Million Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Barclays PLC Buys 46,370 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Best Momentum Stocks to Buy for January 6th - Yahoo Finance
Puma Biotechnology CEO Alan Auerbach sells $106,656 in stock By Investing.com - Investing.com Australia
Puma Biotechnology's SVP sells $27,208 in stock By Investing.com - Investing.com South Africa
Puma Biotechnology chief commercial officer sells $29,742 in stock By Investing.com - Investing.com Australia
Puma Biotechnology chief commercial officer sells $29,742 in stock - Investing.com India
Puma Biotechnology, Inc. (NASDAQ:PBYI) Insider Jeffrey Jerome Ludwig Sells 9,437 Shares - MarketBeat
Alan H. Auerbach Sells 33,841 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock - MarketBeat
Puma Biotechnology’s SVP sells $27,208 in stock By Investing.com - Investing.com Nigeria
Puma Biotechnology CFO sells shares worth $32,232 By Investing.com - Investing.com Australia
Puma Biotechnology CFO sells shares worth $32,232 - Investing.com
Puma Biotechnology's SVP sells $27,208 in stock - Investing.com
Puma Biotechnology CEO Alan Auerbach sells $106,656 in stock - Investing.com
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Franklin Resources Inc. Invests $41,000 in Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
State Street Corp Has $1.53 Million Stake in Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? - MSN
All You Need to Know About Puma Biotech (PBYI) Rating Upgrade to Strong Buy - Yahoo Finance
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why - MSN
Puma biotechnology sales earnings call - Ciudad Florida
Research Analysts Set Expectations for PBYI FY2025 Earnings - Defense World
What Every Investor Should Know: Understanding ROE Can Change Your Game! - Clinique Bio
Best Value Stocks to Buy for December 24th - MSN
Zacks Research Has Positive Outlook of PBYI FY2025 Earnings - MarketBeat
Should You Be Excited About Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 33% Return On Equity? - Simply Wall St
Puma Biotech shares hold as analyst backs Buy rating on NCCN nod - Investing.com Canada
Puma Biotechnology (NASDAQ:PBYI) Given “Buy” Rating at HC Wainwright - Defense World
Best Momentum Stocks To Buy For December 24th - Barchart
Best Momentum Stocks to Buy for December 24th - Yahoo Finance
With 49% stake, Puma Biotechnology, Inc. (NASDAQ:PBYI) seems to have captured institutional investors' interest - Yahoo Finance
Puma Biotechnology's (PBYI) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation - Business Wire
XTX Topco Ltd Sells 22,227 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Acquired by Fmr LLC - Defense World
Puma Biotechnology: The Best Performing Biotechs of 2013 - AOL
Charles Schwab Investment Management Inc. Sells 8,574 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Bought by BNP Paribas Financial Markets - Defense World
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? - Yahoo Finance
Puma biotechnologies 2025 - detikawanua.com
Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward - Seeking Alpha
Puma Biotechnology (NASDAQ:PBYI) Lowered to Buy Rating by StockNews.com - MarketBeat
Finanzdaten der Puma Biotechnology Inc-Aktie (PBYI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):